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Abstract 
 
Some new β-lactams bearing biologically important morpholine ring have been 
synthesized by acylation of amino β-lactams in the presence of morpholine-4-carbonyl 
chloride. These novel β-lactams were prepared under mild reaction conditions without any 
solvent in short reaction times. Their biological activities have been examined against 
microbial agents such as Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), 
Pseudomonas aeruginosa (P. aeruginosa) and fungi such as Candida albicans (C. albicans) 
and Candida glabrata (C. glabrata). They have been also tested against Plasmodium 
falciparum K14 resistant strain and showed moderate to good IC50 values. 
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Introduction 
 
Chemists have always been interested in the 
synthesis of heterocyclic compounds because of 
their important biological activities. b-Lactam 
derivatives, characterized by the presence of an 
azetidine-2-one ring (1) have shown various 
medical applications, due to their low toxicity  
(2). This class of drugs is still in extensive use 
(3) and can be classified into antimalarial (4, 5), 
antimicrobial and antifungal (6),  
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antitubercular (7), antidiabetic (8), anticancer 
(9), antiparkinsonian (10), antitumor (11) and 
anti-HIV (12) agents. Anyway, the wide use of 
these agents have caused the bacteria to produce 
different type of β-lactamases (β-Lases) (13)  
.So, the phenomenon of bacterial resistance 
stimulates a lot of work being devoted to novel 
2-azetidinone derivatives with modification of 
structure of known active compounds (14).  
Urea derivatives have got an important role 
in modern medicinal chemistry because of their 
biological activities (15) such as enzyme 
inhibitors (16), CXCR3 antagonist (17), 
anticonvulsant (18), colchicine-blinding 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Representative examples of some biologically active urea-like compounds. 
 
 
 
 
antagonist (19), and anticancer activities (20). 
Zhu et al. synthesized some urea-like 
compounds such as 1 (21), 2 and 3 (Figure  
1) (22). It was found that incorporating a 
heterocycle, especially a morpholine ring 
exhibited remarkable activity toward human 
cancer cell lines. Although there is less report 
about antifungal and antibacterial activities of 
urea (23), recently a series of N-alkyl 
substituted urea derivatives 4 (Figure 1) (24) 
have been synthesized. In general, the 
compounds bearing morpholine moiety, 
exhibited better antibacterial  
and antifungal activities. In this study we 
report the synthesis of some new modified β-
lactams bearing the biologically important 
morpholine ring under solvent free conditions 
as well as their potent antimicrobial and 
antimalarial activities. 
 
Experimental 
 
General  
All required chemicals were purchased from 
the Merck, and Acros chemical companies. 
CH2Cl2 and Et3N were dried by distillation over 
CaH2 and then stored over 4Å molecular sieves. 
1H NMR and 13C NMR spectra were recorded in 
DMSO-d6 using a Bruker Avance DPX 
instrument (operating at 250 MHz for 1H NMR 
and 62.9 MHz for 13C NMR). Chemical shifts 
were reported in ppm (δ) downfield from TMS. 
All of the coupling constants (J) are in Hertz. IR 
Spectra were run on a Shimadzu FT-IR 8300 
spectrophotometer. Elemental analyses were run 
on a Thermo Finnigan Flash EA-1112 series. 
Melting points were determined in open 
capillaries with a thermo scientific melting point 
 
 
 
 
apparatus. Thin-layer chromatography (TLC) 
was carried out on silica gel 254 analytical 
sheets obtained from Fluka. 
 
General procedure for the synthesis of 
compounds (2a-n)  
A mixture of β-lactams bearing amino 
moiety 1a-n (0.50 mmol) prepared according to 
our previous report (25), morpholine-4-carbonyl 
chloride (1.00 mmol), and Et3N (0.75 mmol) 
were mixed in a mortar and ground with a 
pastle at room temperature for 1.5 h to produce 
new β-lactams 2a-n. The progress of the 
reaction was monitored by TLC. The crude 
product was purified by thick layer 
chromatography (eluent 4:1 CHCl3/EtOAc) to 
yield pure β-lactams 2a-n. 
 
4-(4-Aminophenyl)-1-(4-methoxyphenyl)-3-
(naphthalen-2-yloxy) - azetidine-2-one (1d)  
White crystals, yield 65%, mp: 150-152 °C;  
IR (KBr, cm−1): 1730 (CO, β-lactam), 3388,  
3475 (NH2). 
1
H-NMR (DMSO-d6) δ (ppm): 
3.68 (OMe, s, 3H), 5.01 (NH2, s, 2H), 5.56 (H-
4, d, J = 4.6 Hz, 1H), 5.85 (H-3, d, J = 4.6 Hz, 
1H), 6.35 (ArH, d, J = 8.4 Hz, 2H), 6.88–7.78 
(ArH, m, 13H). 13C-NMR (DMSO-d6) δ (ppm): 
55.2 (OMe), 61.1 (C-4), 80.5 (C-3), 198.6, 
113.4, 114.4, 117.9, 118.5, 119.1, 123.9, 126.4, 
126.7, 127.5, 128.8, 128.9, 129.2, 130.3, 133.7,  
148.6, 154.3, 155, 8 (aromatic carbons), 162.1 
(CO, β-lactam). Anal. Calcd. for C26H22N2O3: 
C, 76.08; H, 5.40; N, 6.82. Found: C, 76.19; H, 
5.63; N, 6.87%. 
 
4-(4-Aminophenyl)-3-(4-chlorophenoxy)-1-
(4-ethoxyphenyl)-azetidine-2-one (1e)  
White solid, yield 57%, mp: 164-168 °C; 
 IR (KBr, cm−1): 1743 (CO, β-lactam), 3379, 129.2, 130.2, 148.7, 155.0, 156.6 (aromatic 
3479 (NH2). 
1
H-NMR (DMSO-d6) δ (ppm): carbons), 162.2 (CO, β-lactam). Anal. Calcd. 
1.26 (Me, t, J = 7.0 Hz, 3H), 3.92 (OCH2, q, J for C23H22N2O3: C, 73.78; H, 5.92; N, 7.48. 
= 7.0 Hz, 2H), 5.06 (NH2, s, 2H), 5.53 (H-4, d, Found: C, 73.86; H, 6.03; N, 7.35%.      
J = 4.6 Hz, 1H), 5.69 (H-3, d, J = 4.6 Hz, 1H),          
6.36 (ArH, d, J = 8.4 Hz, 2H), 6.79 (ArH, d, J 4-(4-Aminophenyl)-1-(4-ethoxyphenyl)-3- 
= 9.0 Hz, 2H), 6.84 (ArH, d, J = 9.0 Hz, 2H), (naphthalen-2-yloxy) azetidine-2-one (1h)   
6.95 (ArH, d, J = 8.4 Hz, 2H), 7.17 (ArH, d, J Light brown solid, yield 94%, mp: 160-162 
= 9.0 Hz, 2H), 7.18 (ArH, d, J = 9.0 Hz, 2H). °C; IR (KBr, cm−1): 1735 (CO, β-lactam), 3379, 
13C-NMR (DMSO-d6) δ (ppm): 14.5 (Me), 60.9 3465 (NH2). 
1
H-NMR (DMSO-d6) δ (ppm): 
(OCH2), 63.1 (C-4), 80.4 (C-3), 113.4, 114.9, 1.23 (Me, t, J = 7.0 Hz, 3H), 3.93 (OCH2, q, J = 
116.7, 118.5, 118.9, 125.2, 128.9, 130.1, 148.7, 7.0 Hz, 2H), 4.99 (NH2, s, 2H), 5.55 (H-4, d, J = 
155.1, 155.3 (aromatic carbons), 161.8 (CO, 4.6 Hz, 1H), 5.83 (H-3, d, J = 4.6 Hz, 1H), 6.34 
β-lactam). Anal. Calcd. for C23H21ClN2O3: C, (ArH, d, J = 8.4 Hz, 2H), 6.86 (ArH, d, J = 9.0 
67.56; H, 5.18; N, 6.85. Found: C, 67.47; H, Hz, 2H), 6.96–7.32 (ArH, m, 8H), 7.67 (ArH, 
5.20; N, 6.78%.      d, J = 9.0 Hz, 1H), 7.74 (ArH, d, J = 9.0 Hz, 
         2H). 13C-NMR (DMSO-d6) δ (ppm): 14.5 (Me), 
4-(4-Aminophenyl)-3-(2,4-dichlorophenoxy)- 61.1 (OCH2), 63.1 (C-4), 80.4 (C-3), 108.5, 
1-(4-ethoxyphenyl) azetidine-2-one (1f)  113.4, 114.9, 117.9, 118.5, 119.1, 123.9, 126.4, 
White solid, yield 71%, mp: 196-198 °C; IR 126.7, 127.5, 128.8, 128.9, 129.2, 130.2, 133.7, 
(KBr, cm−1): 1759 (CO, β-lactam), 3350, 3475 148.6, 154.3, 155.1 (aromatic carbons), 162.1 
(NH 
2 
). 1H-NMR (DMSO-d 
6 
) δ (ppm): 1.26 (CO, β-lactam). Anal. Calcd. for C H 
24 
N O : 
          27 2 3 
(Me, t, J = 6.9 Hz, 3H), 3.93 (OCH2, q, J = 6.9 C, 76.39; H, 5.70; N, 6.60. Found: C, 76.35; H, 
Hz, 2H), 5.07 (NH2, s, 2H), 5.45 (H-4, d, J = 5.84; N, 6.63%.       
4.5 Hz, 1H), 5.82 (H-3, d, J = 4.5 Hz, 1H), 6.36          
(ArH, d, J = 8.4 Hz, 2H), 6.85 (ArH, d, J = 8.9 4-(4-Aminophenyl)-3-(4-chlorophenoxy)-1- 
Hz, 2H), 6.97 (ArH, d, J = 8.4 Hz, 2H), 7.05 (4-methoxybenzyl) azetidine-2-one (1i)     
(ArH, d, J = 8.9 Hz, 1H), 7.19–7.28 (ArH, m, Cream solid, yield 75%, mp: 160-162 °C; 
3H), 7.41 (ArH, s, 1H). 13C-NMR (DMSO-d ) IR (KBr, cm−1): 1749 (CO, β-lactam), 3379, 
       6 
3456 (NH2). 
1
H-NMR (DMSO-d6) δ (ppm): δ (ppm): 14.5 (Me), 60.6 (OCH2), 63.1 (C-4), 
80.5 (C-3), 113.4, 114.9, 115.8, 118.5, 122.0, 3.71 (OMe, s, 3H), 3.72 (CH2, d, J = 15.1, 1H), 
125.4, 127.6,  128.9,  129.2,  130.0,  148.8, 4.57 (CH2, d, J = 15.1, 1H), 4.77 (H-4, d, J = 
150.8, 155.1 (aromatic carbons), 161.2 (CO, 4.2 Hz, 1H), 5.06 (NH2, s, 2H), 5.52 (H-3, d, J 
β-lactam). Anal. Calcd. for C23H20Cl2N2O3: C, = 4.2 Hz, 1H), 6.38 (ArH, d, J = 8.4 Hz, 2H), 
62.31; H, 4.55; N, 6.32. Found: C, 62.46; H, 6.75 (ArH, d, J = 9.0 Hz, 2H), 6.84 (ArH, d, J 
4.69; N, 6.31%.      = 8.4 Hz, 2H), 6.85 (ArH, d, J = 8.7 Hz, 2H), 
         7.06 (ArH, d, J = 8.7 Hz, 2H), 7.12 (ArH, d, J 
4-(4-Aminophenyl)-1-(4-ethoxyphenyl)-3- = 9.0 Hz, 2H). 13C-NMR (DMSO-d6) δ (ppm): 
phenoxy azetidin-2-one (1g)     42.5 (CH2), 55.0 (OMe) 60.4 (C-4), 81.3 (C-3), 
White solid, yield 87%, mp: 182-184 °C; IR 113.4, 113.9, 116.6, 118.9, 125.0, 127.3, 128.9, 
(KBr, cm−1): 1736 (CO, β-lactam), 3350, 3446 129.1, 129.3, 148.6, 155.3, 158.6 (aromatic 
(NH2). 
1
H-NMR (DMSO-d6) δ (ppm): 1.28 carbons), 164.5 (CO, β-lactam). Anal. Calcd. 
(Me, t, J = 6.8 Hz, 3H), 3.93 (OCH2, q, J = 6.8 for C23H21ClN2O3: C, 67.56; H, 5.18; N, 6.85. 
Hz, 2H), 5.05 (NH2, s, 2H), 5.43 (H-4, d, J = Found: C, 67.78; H, 5.25; N, 7.00%.      
4.4 Hz, 1H), 5.68 (H-3, d, J = 4.4 Hz, 1H), 6.38          
(ArH, d, J = 8.0 Hz, 2H), 6.78–6.87 (ArH, m, 4-(3-Aminophenyl)-3-(4-chlorophenoxy)-1- 
5H), 6.98 (ArH, d, J = 8.0 Hz, 2H), 7.11–7.23 (4-methoxy phenyl) azetidine-2-one (1k)    
(ArH, m, 4H). 13C-NMR (DMSO-d ) δ (ppm): White solid, yield 95%, mp: 174-176 °C; IR 
14.5 (Me), 61.1 (OCH 
  6  
(KBr, cm−1): 1747 (CO, β-lactam), 3369, 3437 ), 63.1 (C-4), 80.4 (C-3), 
   2     
(NH ). 1H-NMR (DMSO-d ) δ (ppm): 3.68 113.4, 114.9, 115.0, 118.5, 119.2, 121.5, 128.9, 
         2  6      
 
 
 
(OMe, s, 3H), 5.04 (NH2, s, 2H), 5.18 (H-4, d, J 
= 4.7 Hz, 1H), 5.39 (H-3, d, J = 4.7 Hz, 1H), 
6.64–7.00 (ArH, m, 8H), 7.20 (ArH, d, J = 8.9 
Hz, 4H). 13C-NMR (DMSO-d6) δ (ppm): 55.2 
(OMe), 61.1 (C-4), 80.6 (C-3), 112.7, 114.0, 
114.5, 115.8, 116.9, 118.4, 125.4, 128.6, 129.0, 
129.3, 133.4, 148.4, 155.5, 155.9 (aromatic 
carbons), 161.8 (CO, β-lactam). Anal. Calcd. 
for C22H19ClN2O3: C, 66.92; H, 4.85; N, 7.09.  
Found: C, 66.85; H, 4.64; N, 7.16%. 
 
N - ( 4 - ( 1 - ( 4 - m e t h o x y p h e n y l ) - 
4 - o x o - 3 - phenoxyazetidin-2-
yl)phenyl)morpholine-4 carboxamide (2a)  
White powder, yield 88%, mp: 194-196 °C; 
IR (KBr, cm-1): 1666 (CO, urea), 1739 (CO, β-
lactam), 3458 (NH). 1H NMR (DMSO-d6) δ 
(ppm): 3.35 (m, 4H, CH2-N), 3.52 (m, 4H, 
CH2-O), 3.67 (s, 3H, OMe), 5.58 (d, J 4.6 Hz, 
1H, H-4), 5.76 (d, J 4.6 Hz, 1H, H-3), 6.79–
7.36 (m, 13H, ArH), 8.51 (s, 1H, NH, D2O 
exchange). 13C NMR (62.9 MHz, DMSO-d6) δ 
(ppm): 44.1 (CH2-N), 55.2 (OMe), 60.7 (C-4), 
65.9 (CH2-O), 80.5 (C-3), 114.5, 114.9, 118.5, 
119.1, 121.7, 126.0, 128.2, 129.3, 130.1, 140.4, 
155.8, 156.5 (aromatic carbons),  
154.9 (CO, urea), 162.1 (CO, β-lactam); Anal. 
calcd for C27H27N3O5 (473.52): C, 68.48; H, 
5.75; N, 8.87%. Found: C, 68.44; H, 5.77; N 
8.85%. 
 
N-(4-(3-(2,4-dichlorophenoxy)-1-(4-
methoxyphenyl)-4-oxoazetidin-2-yl)phenyl) 
morpholine-4-carboxamide (2b)  
White powder, yield 73%, mp: 144-146 °C; 
IR (KBr, cm-1): 1643 (CO, urea), 1751 (CO, β-
lactam); 3456 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.42 (m, 4H, CH2-N), 3.53 
(m, 4H, CH2-O), 3.67 (s, 3H, OMe), 5.61 (d, J 
4.6 Hz, 1H, H-4), 5.89 (d, J 4.6 Hz, 1H, H-3),  
6.88–7.43 (m, 11H, ArH), 8.51 (s, 1H, NH, D2O 
exchange). 13C NMR (62.9 MHz, DMSO-d6) δ 
(ppm): 44.3 (CH2-N), 55.4 (OMe), 60.5 (C-4), 
66.1 (CH2-O), 80.8 (C-3), 114.7, 116.1, 118.7, 
119.2, 122.3, 125.5, 125.8, 127.9, 128.5, 129.5, 
130.1, 140.8, 150.9, 156.2 (aromatic carbons),  
155.0 (CO, urea), 161.4 (CO, β-lactam); Anal. 
calcd for C27H25Cl2N3O5 (542.41): C, 59.79; H, 
4.65; N, 7.75%. Found: C, 59.75; H, 4.67; N  
7.71%. 
 
 
N - ( 4 - ( 3 - ( 4 - c h l o ro p h e n o x y ) - 1 
- ( 4 - methoxyphenyl)-4-oxoazetidin-2-
yl)phenyl) morpholine-4-carboxamide (2c)  
White powder, yield 66%, mp: 158-160 °C; 
IR (KBr, cm-1): 1666 (CO, urea), 1735 (CO, β-
lactam), 3418 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.04 (m, 4H, CH2-N), 3.33 
(m, 4H, CH2-O), 3.67 (s, 3H, OMe), 5.44 (d, J 
4.5 Hz, 1H, H-4), 5.77 (d, J 4.5 Hz, 1H, H-3,),  
6.81–7.35 (m, 12H, ArH), 8.52 (s, 1H, NH, 
D2O exchange). 13C NMR (62.9 MHz, DMSO-
d6) δ (ppm): 44.1 (CH2-N), 55.2 (OMe), 60.5 
(C-4), 65.9 (CH2-O), 80.5 (C-3), 114.5, 116.7, 
118.5, 119.0, 125.4, 125.7, 128.2, 129.0, 130.0, 
140.4, 155.2, 155.9 (aromatic carbons), 154.9 
(CO, urea), 161.7 (CO, β-lactam); Anal. calcd 
for C27H26ClN3O5 (507.97): C, 63.84; H, 5.16; 
N, 8.27%. Found: C, 63.78; H, 5.15; N, 8.30%. 
 
N-(4-(1-(4-methoxyphenyl)-3-(naphthalen-2 
- y l o x y ) - 4 - o x o a z e t i d i n - 2 - y l ) p h 
e n y l ) morpholine-4-carboxamide (2d)  
White powder, yield 95%, mp: 206-208 °C; 
IR (KBr, cm−1): 1658 (CO, urea), 1743 (CO, β-
lactam), 3425 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.34 (m, 4H, CH2-N), 3.42 
(m, 4H, CH2-O), 3.67 (s, 3H, OMe), 5.69 (d, J 
4.5 Hz, 1H, H-4), 5.91 (d, J 4.5 Hz, 1H, H-3), 
6.88–7.78 (m, 15H, ArH), 8.46 (s, 1H, NH, 
D2O exchange). 13C NMR (62.9 MHz, DMSO-
d6) δ (ppm): 44.0 (CH2-N), 55.2 (OMe), 60.7 
(C-4), 65.9 (CH2-O), 80.5 (C-3), 108.6, 114.5, 
117.8, 118.5, 119.0, 124.0, 125.9,  
126.5, 126.7, 127.5, 128.2, 128.8, 129.3, 130.1,  
133.6, 140.4, 154.8, 155.8 (aromatic carbons),  
154.2 (CO, urea), 161.9 (CO, β-lactam); Anal. 
calcd for C31H29N3O5 (523.58): C, 71.11; H, 
5.58; N, 8.03%. Found: C, 71.15; H, 5.54; N,  
8.00%. 
 
N - ( 4 - ( 3 - ( 4 - c h l o ro p h e n o x y ) - 1 
- ( 4 - ethoxyphenyl)-4-oxoazetidin-2-yl)phenyl) 
morpholine-4-carboxamide (2e)  
White powder, yield 69%, mp: 216-218 °C; 
IR (KBr, cm−1): 1666 (CO, urea), 1743 (CO, β-
lactam), 3425 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 1.23 (m, 3H, Me), 3.37 (m, 
4H, CH2-N), 3.53 (t, 4H, CH2-O), 3.89 (q, 2H, 
OCH 2), 5.57 (d, J 4.6 Hz, 1H, H-4), 5.77 (d, J 
4.6 Hz, 1H, H-3), 6.81–7.41 (m, 15H, 
 
 
 
ArH), 8.49 (s, 1H, NH, D2O exchange). 13C 
NMR (62.9 MHz, DMSO-d6) δ (ppm): 14.5 
(Me), 44.1 (CH2-N), 60.5 (C-4), 63.1 (OCH2), 
65.9 (CH2-O), 80.5 (C-3), 114.9, 116.7, 118.5, 
119.0, 125.4, 125.7, 128.2, 129.0, 129.9, 140.4, 
155.2, 155.2 (aromatic carbon), 154.9 (CO, 
urea), 161.7 (CO, β-lactam); Anal. calcd for 
C28H28ClN3O5 (521.99): C, 64.43; H, 5.41; N, 
8.05%. Found: C, 64.40; H, 5.42; N, 8.09%. 
 
N - ( 4 - ( 3 - ( 2 , 4 - d i c h l o ro p h e n o x 
y ) - 1 - ( 4 - ethoxyphenyl)-4-oxoazetidin-2-
yl)phenyl) morpholine-4-carboxamide (2f)  
White powder, yield 79%, mp: 192-194 °C; 
IR (KBr, cm−1): 1664 (CO, urea), 1740 (CO, β-
lactam), 3405 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 1.21 (m, 3H, Me), 3.32 (m, 
4H, CH2-N), 3.53 (m, 4H, CH2-O), 3.89 (q, 2H, 
OCH2), 5.60 (d, J 4.3 Hz, 1H, H-4), 5.89 (d, J 
4.3 Hz, 1H, H-3), 6.85–7.42 (m, 11H, ArH), 
8.51 (s, 1H, NH, D2O exchange). 13C NMR 
(62.9 MHz, DMSO-d6) δ (ppm): 14.5 (Me), 
44.0 (CH2-N), 60.2 (C-4), 63.1 (OCH2), 65.9 
(CH2-O), 80.6 (C-3), 113.1, 114.9, 115.9, 
118.5, 118.9, 122.0, 125.3, 127.7, 128.2, 129.2, 
129.8, 140.4, 150.9, 155.2 (aromatic carbons),  
154.8 (CO, urea), 164.2 (CO, β-lactam); Anal. 
calcd for C28H27Cl2N3O5 (556.44): C, 60.44; H, 
4.89; N, 7.55%. Found: C, 60.49; H, 4.90; N,  
7.49%. 
 
N - (4 - (1 - (4 - ethoxyphenyl) - 4 - oxo - 3 - 
phenoxyazetidin-2-yl)phenyl) morpholine-4-
carboxamide (2g)  
White powder, yield 92%, mp: 206-208 °C; 
IR (KBr, cm−1): 1670 (CO, urea), 1747 (CO, β-
lactam), 3419 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 1.23 (m, 3H, Me), 3.33 (m, 
4H, CH 2-N), 3.52 (t, 4H, CH2-O), 3.91 (q, 2H, 
OCH2), 5.57 (d, J 4.6 Hz, 1H, H-4), 5.75 (d, J 
4.6 Hz, 1H, H-3), 6.79–7.36 (m, 13H, ArH), 
8.55 (s, 1H, NH, D2O exchange). 13C NMR 
(62.9 MHz, DMSO-d6) δ (ppm): 14.5 (Me), 
44.1 (CH2-N), 61.1 (C-4), 63.1 (OCH2), 65.9 
(CH2-O), 80.4 (C-3), 113.5, 114.9, 118.4, 
119.0, 121.7, 125.9, 128.2, 129.3, 130.0, 140.4, 
155.1, 156.5 (aromatic carbons), 154.9 (CO, 
urea), 162.1 (CO, β-lactam); Anal. calcd for 
C28H29N3O5 (487.55): C, 68.98; H, 6.00; N,  
8.62%. Found: C, 69.01; H, 6.03; N, 8.65%. 
 
 
 
N-(4-(1-(4-ethoxyphenyl)-3-(naphthalen-2-
yloxy)-4-oxoazetidin-2-yl)phenyl) morpholine-
4-carboxamide (2h)  
White powder, yield 75%, mp: 221-223 °C; 
IR (KBr, cm−1): 1658 (CO, urea), 1743 (CO, β-
lactam), 3433 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 1.23 (m, 3H, Me), 3.33(m, 
4H, CH2-N), 3.49 (t, 4H, CH2-O), 3.89 (q, 2H, 
OCH2), 5.69 (d, J 4.6 Hz, 1H, H-4), 5.90 (d, J 
4.6 Hz, 1H, H-3), 6.87–7.79 (m, 15H, ArH), 
8.47 (s, 1H, NH, D2O exchange). 13C NMR (62.9 
MHz, DMSO-d6) δ (ppm): 14.5 (Me), 44.0 (CH2-
N), 60.72 (C-4), 63.1 (OCH2), 65.9 (CH2-O), 80.5 
(C-3), 108.5, 114.9, 117.8, 118.5, 118.9, 124.0, 
125.9, 126.5, 126.7, 127.5, 128.2, 128.8, 129.3, 
130.0, 133.6, 140.3, 154.8, 155.1 (aromatic 
carbons), 154.2 (CO, urea), 161.9 (CO, β-lactam); 
Anal. calcd for C32H31N3O5  
(537.61): C, 71.49; H, 5.81; N, 7.82%. Found:  
C, 71.56; H, 5.79; N, 7.79%. 
 
N - ( 4 - ( 1 - ( 4 - m e t h o x y b e n z y l ) - 3 
- ( 4 - chlorophenoxy)-4-oxoazetidin-2-
yl)phenyl) morpholine-4-carboxamide (2i)  
White powder, yield 89%, mp: 186-188 °C; 
IR (KBr, cm−1): 1663 (CO, urea), 1744 (CO, β-
lactam), 3433 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.49 (m, 4H, CH2-N), 3.62 
(m, 4H, CH2-O), 3.80 (s, 3H, OMe), 3.88(d, J 
15.2 Hz, 1H, CH2), 4.69 (d, J 15.2 Hz, 1H, 
CH2), 4.98 (d, J 4.3 Hz, 1H, H-4), 5.68 (d, J 4.3 
Hz, 1H, H-3), 6.85–7.43 (m, 12H, ArH), 8.58 
(s, 1H, NH, D2O exchange). 13C NMR (62.9 
MHz, DMSO-d6) δ (ppm): 42.8 (CH2), 44.1 
(CH2-N), 55.0 (OMe), 60.2 (C-4), 65.9 (CH2-
O), 81.3 (C-3), 113.9, 116.6, 118.9, 125.1, 
125.9, 127.1, 128.4, 128.9, 129.4, 140.3,  
155.2, 158.6 (aromatic carbons), 154.9 (CO, 
urea), 164.4 (CO, β-lactam); Anal. calcd for 
C28H28ClN3O5 (521.99): C, 64.43; H, 5.41; N, 
8.05%. Found: C, 64.40; H, 5.37; N, 8.09%. 
 
N - (4 - (1 - (4 - chlorophenyl) - 4 - oxo - 3 - 
phenoxyazetidin-2-yl)phenyl) morpholine-4-
carboxamide (2j)  
White powder, yield 45%, mp: 235-237 °C; 
IR (KBr, cm−1): 1658 (CO, urea), 1751 (CO, β-
lactam), 3418 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.33 (m, 4H, CH2-N), 3.52 
(m, 4H, CH2-O), 5.64 (d, J 4.8 Hz, 1H, H-4), 
  
5.81 (d, J 4.8 Hz, 1H, H-3), 6.79–7.42 (m, 
13H, ArH,), 8.53 (s, 1H, NH, D2O exchange). 
13C NMR (62.9 MHz, DMSO-d6) δ (ppm): 
44.1 (CH2-N), 60.8 (C-4), 65.9 (CH2-O), 
80.6 (C-3), 114.9, 118.7, 119.1, 121.8, 125.4, 
127.9, 128.2, 129.3, 129.3, 135.5, 140.5, 156.4 
(aromatic carbons), 154.9 (CO, urea), 162.9 
(CO, β-lactam); Anal. calcd for C26H24ClN3O4  
(477.94): C, 65.34; H, 5.06; N, 8.79%. Found:  
C, 65.28; H, 5.07; N, 8.73%. 
 
N - ( 3 - ( 3 - ( 4 - c h l o r o p h e n o x y ) - 
1 - ( 4 - methoxyphenyl)-4-oxoazetidin-2-
yl)phenyl) morpholine-4-carboxamide (2k)  
White powder, yield 89%, mp: 114-116 °C; 
IR (KBr, cm−1): 1639 (CO, urea), 1739 (CO, β-
lactam), 3465 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.35 (m, 4H, CH2-N), 3.53 
(m, 4H, CH2-O), 3.67 (s, 3H, OMe), 5.56 (d, J 
4.4 Hz, 1H, H-4), 5.81 (d, J 4.4 Hz, 1H, H-3),  
6.82–7.82 (m, 12H, ArH), 8.61 (s, 1H, NH, D2O 
exchange). 13C NMR (62.9 MHz, DMSO-d6) δ 
(ppm): 44.1 (CH2-N), 55.2 (OMe), 60.9 (C-4), 
65.9 (CH2-O), 80.6 (C-3), 114.5, 116.9, 118.4, 
119.5, 121.8, 125.5, 128.1, 129.0, 129.1, 130.1, 
133.1, 140.4, 155.3, 155.9 (aromatic carbons),  
154.9 (CO, urea), 161.7 (CO, β-lactam); Anal. 
calcd for C27H26ClN3O5 (507.97): C, 63.84; H, 
5.16; N, 8.27%. Found: C, 63.83; H, 5.19; N,  
8.32%. 
 
N-(3-(3-(2,4-dichlorophenoxy)-1-(4-
methoxyphenyl)-4-oxoazetidin-2-yl)phenyl) 
morpholine-4- carboxamide (2l)  
White powder, yield 74%, mp: 140-142 °C; 
IR (KBr, cm−1): 1637 (CO, urea), 1767 (CO, β-
lactam), 3286 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.34 (m, 4H, CH2-N), 3.53 
(m, 4H, CH2-O), 3.68 (s, 3H, OMe), 5.59 (d, J 
4.7 Hz, 1H, H-4), 5.92 (d, J 4.7 Hz, 1H, H-3),  
6.89–7.48 (m, 11H, ArH), 8.53 (s, 1H, NH, 
D2O exchange). 13C NMR (62.9 MHz, DMSO-
d6) δ (ppm): 44.1 (CH2-N), 55.2 (OMe), 60.6 
(C-4), 65.9 (CH2-O), 80.7 (C-3), 114.5, 116.2, 
118.4, 118.4, 119.4, 121.7, 122.3, 125.7, 127.7, 
128.0, 129.3, 130.0, 132.8, 140.4, 150.8, 156.0 
(aromatic carbons), 154.9 (CO, urea), 161.2 
(CO, β-lactam); Anal. calcd for C27H25Cl2N3O5  
(542.41): C, 59.79; H, 4.65; N, 7.75%. Found:  
C, 59.81; H, 4.64; N, 7.71%. 
 
 
N-(3-(1-(4-methoxyphenyl)-4-oxo-3-
phenoxyazetidin-2-yl)phenyl) morpholine-4-
carboxamide (2m)  
White powder, yield 68%, mp: 123-125 °C; 
IR (KBr, cm−1): 1643 (CO, urea), 1743 (CO, β-
lactam), 3418 (NH). 1H NMR (250 MHz, 
DMSO-d6) δ (ppm): 3.33 (m, 4H, CH2-N), 3.43 
(m, 4H, CH 2-O) 3.68 (s, 3H, OMe), 5.57 (d, J 
4.7 Hz, 1H, H-4), 5.79 (d, J 4.7 Hz, 1H, H-3),  
6.80–7.48 (m, 13H, ArH), 8.63 (s, 1H, NH, D2O 
exchange). 13C NMR (62.9 MHz, DMSO-d6) δ 
(ppm): 44.1 (CH2-N), 55.2 (OMe), 61.1 (C-4), 
65.9 (CH2-O), 80.6 (C-3), 114.5, 115.2, 118.4, 
118.4, 119.5, 121.8, 121.9, 128.1, 129.3, 130.2, 
133.4, 140.4, 155.9, 156.6 (aromatic carbons),  
154.9 (CO, urea), 162.2 (CO, β-lactam); Anal. 
calcd for C27H27N3O5 (473.52): C, 68.48; H, 
5.75; N, 8.87%. Found: C, 68.40; H, 5.79; N,  
8.93%. 
 
N-(3-(1-(4-methoxyphenyl)-3-(naphthalen-2 
- y l o x y ) - 4 - o x o a z e t i d i n - 2 - y l ) p h 
e n y l ) morpholine-4-carboxamide (2n)  
White powder, yield 63%, mp: 220-222 °C; IR 
(KBr, cm−1): 1674 (CO, urea), 1743 (CO, β-
lactam), 3441 (NH). 1H NMR (250 MHz, DMSO-
d6) δ (ppm): 3.32 (m, 4H, CH2-N) , 3.52 (m, 4H, 
CH 2-O) 3.68 (s, 3H, OMe), 5.68 (d, J 4.7 Hz, 1H, 
H-4), 5.95 (d, J 4.7 Hz, 1H, H-3),  
6.90–7.78 (m, 15H, ArH), 8.51 (s, 1H, NH, D2O 
exchange). 13C NMR (62.9 MHz, DMSO-d6) δ 
(ppm): 44.0 (CH2-N), 55.2 (OMe), 61.1 (C-4), 
65.9 (CH2-O), 80.6 (C-3), 108.9, 114.5, 117.9, 
118.4, 118.4, 119.4, 121.9, 124.1, 126.5, 126.7, 
127.4, 128.1, 128.9, 129.3, 130.2, 133.4, 133.6,  
140.3, 154.9, 155.9 (aromatic carbon), 154.3 
(CO, urea), 162.0 (CO, β-lactam); Anal. calcd 
for C31H29N3O5 (523.58): C, 71.11; H, 5.58; N, 
8.03%. Found: C, 71.18; H, 5.55; N, 8.04%. 
 
General procedure for antimalarial activity The  
chloroquine  resistant  P.  falciparum strain K14 
(Southeast Asia) was maintained in type O+ 
human red blood cells in complete medium  
supplemented  with  10%  human serum, at 37 
°C, under an atmosphere of 85% N2/5% O2/5% 
CO2 (26). The cultures were synchronized by 
sorbitol treatment (27) parasite sensitivity to β-
lactams was determined using the in-vitro 
isotopic microtest (28). Briefly, the 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1. Synthesis of compounds 2a-n. 
 
 
 
 
parasites were cultured (synchronized at ring 
stage containing 0.8% parasitemia and 1.5% 
hematocrit) in the presence of serial dilutions of 
β-lactam derivatives.  
The parasite growth was assessed by adding 
1 µCi of tritiated hypoxanthine with a specific 
activity of 14.1 Ci/mmol (Perkin-Elmer, 
Courtaboeuf, France) to each well at time zero. 
After 48 h of culturing, the plates were freeze-
thawed and harvested on filters. The dried 
filters were moistened in a scintillation liquid 
mixture (Microscint O, Perkin-Elmer) and the 
radioactivity incorporated into parasite nucleic 
acid was counted using a Top Count Microbeta 
counter (Perkin-Elmer). Drug concentrations 
inhibiting parasite growth by 50% (IC50) were 
calculated using nonlinear regression analysis 
of the dose-response curves (Riasmart; Packard, 
Meridem, USA). The reference antimalarial 
drug used was chloroquine. The IC50 for 
chloroquine of the K14 strain was 1147.5 ± 
31.8 nM. 
 
Results and Discussion 
Chemistry 
 
β-lactams bearing the amino group 1a-n 
were treated with morpholine-4-carbonyl 
chloride and triethylamine under solvent free 
grinding condition to afford the -corresponding 
β-lactams 2a-n in moderate to high yields 
(Scheme 1 and Table 1). Using the optimized 
reaction conditions, β-lactams 1a-n were 
converted into their corresponding β-lactams 
2a-n in moderate-to-excellent yields. These 
newly synthesized 2-azetidinones have been 
 
 
 
 
characterized by spectral data and elemental 
analyses.  
In the IR spectra of compounds 2a-n, a sharp 
band in the region at 1735-1767 cm-1 is assigned 
to the stretching of ν (C=O, b-lactam). Presence of 
this band is a critical step in the proof of the b-
lactam structure of these compounds (29). All of 
these compounds showed a peak at 1637-1674 cm-
1 due to ν (C=O, urea), that is an evidence of the 
formation of desired products. In addition, the IR 
spectra of 2a-n exhibited the –NH stretching 
between 3286-3465 cm-1.  
1H NMR spectra of the compounds 2a-h and 
2j-n displayed H-3 and H-4 protons of b-lactam 
ring between 5.75-5.95 and 5.44-5.69 ppm and 2i 
showed H-3 and H-4 protons at 5.67 and 4.98 
ppm as doublet. The observed coupling constants 
(J = 4.3-4.7 Hz) for H-4 and (J = 4.3-4.7 Hz) for 
H-3 confirmed the cis stereochemistry for all of 
these compounds (30). 2i exhibited the benzylic 
protons at 3.88 and 4.69 ppm as doublets. The 
spectra of compounds 2a-d, 2i, and 2k-n also 
displayed the methoxy proton peak as singlet. The 
morpholine ring›s protons in all cases appeared as 
two multiplets. 1H NMR spectra of all compounds 
also displayed the -NH proton (D2O 
exchangeable) as a singlet in the region at 8.46-
8.63 ppm. 13C NMR spectra of compounds 2a-n 
displayed b-lactam carbonyl peak at 161.4-164.4 
ppm. Urea carbonyl peak appeared in the region at 
154.2-155.0 ppm. Carbon of morpholine ring 
(CH2-O) for 2b was appeared at 66.1 and for the 
other compounds was appeared at 65.9 ppm. All 
compounds showed carbons of morpholine ring 
(CH2-N) between 44.0-44.3 ppm. 
 
Table 1. Synthesis of β-lactams 2a-n under solvent free grinding conditiona, b.   
Scaffold  Entry 
R
1 
R
2 Entry Yield (%)  Scaffold      
     1a 
C6H5 4-MeOC6H4 2a 88 
          
     (ref 25)           
                   
     1b 
2,4-Cl2C6H3 4-MeOC6H4 2b 73 
          
     (ref 25)           
                   
     1c 
4-ClC6H4 4-MeOC6H4 2c 66 
          
    
NH2 )ref 25( 
        
O          
N 
 
OR1 
H H 
 
1d Naphth-2-yl 4-MeOC6H4 2d 95 
    
HN 
  
        
     O 
     
1e 4-ClC6H4 4-EtOC6H4 2e 69 OR1 
H H       
  
N 
       
         
O R 2 1f 2,4-Cl2C6H3 4-EtOC6H4 2f 79 O 
   
R 2 
     
        
 
1a-1j 1g C6H5 4-EtOC6H4 2g 92 
  
N 
2a-2j 
     
        
          
     1h Naphth-2-yl 4-EtOC6H4 2h 75           
     1i 4-ClC6H4 4-MeOC6H4CH2 2i 89           
     1j 
C6H5 4-ClC6H4 2j 45 
          
     )ref 25(           
                   
                     
 
     1k 
OR1 
H H 
NH2 1l 
     
)ref 25(      
  N  
1m 
   
O R 2 
     )ref 25(  
1k-1n 1n 
 
 )ref 25( 
 
4-ClC6H4 4-MeOC6H4 
 
2,4-Cl2C6H3 4-MeOC6H4 
 
C6H5 4-MeOC6H4 
 
Naphth-2-yl 4-MeOC6H4 
 
 
2k 89          
O 
           
2l 74 
OR1 
H H N 
N 
 
  
 
  
O 
  
      H 
             
2m 68 O 
  
N 
R 2 
     
       
         
2n 63 
     2k-2n      
            
 
aAll products were characterized by IR, 1H NMR, 13C NMR and elemental analyses.  
bIsolated yield after silica gel chromatography. 
 
 
 
 
 
 
Antimicrobial and antibacterial screening 
(in-vitro)  
All of these newly synthesized β-lactams 
derivatives were subsequently evaluated for 
their biological activities. First of all, it has 
been demonstrated that these compounds do not 
possess significant antimicrobial efficiency 
against Gram-positive S. aureus and Gram-
negative bacteria E. coli or P. aeruginosa and 
fungi such as C.albicans and C. glabrata with 
MICs values greater than 125 µg/mL in all 
cases. Based on their structural properties, these 
compounds may not be useful as chelating 
agents with potential activity. The results of 
present investigation support the suggested 
structures of hypothetical antibacterial 
pharmacophore site. It has been suggested that 
 
 
 
 
 
 
some functional groups such as azomethine 
cotaining hetero-aromatics as arm, constitutes 
the essential pharmacophore site (N --- N) or (N 
--- O) displayed role of antibacterial activity 
that may be responsible for the increase of 
hydrophobic character and liposolubility of 
molecules. This in turn, enhances activity of the 
compounds and biological absorbance, so as, all 
of the synthesized β-lactams bearing the amino 
group 1a-n and 2a-n have low antibacterial 
properties.  
A number of important points emerge 
concerning the electronic and steric factors 
which have direct impact on bioactivity 
properties.  
The positive results we have recorded, while 
encouraging for purposes of new drug 
  
Table 2. Antimalarial activity of the new β-lactam derivatives 1a-n and 2a-n.   
Entry. IC50 (µM) P. falciparum K14 Entry. IC50 (µM) P. falciparum K14 
    
1a >50 2a 41 
1b 50.0 2b 21 
1c >50 2c 30 
1d >50 2d 41 
1e >50 2e >50 
1f >50 2f >50 
1g >50 2g >50 
1h >50 2h >50 
1i >50 2i >50 
1j 41 2j 26 
1k >50 2k 39 
1l >50 2l 32 
1m >50 2m >50 
1n >50 2n 50   
aThe standard antimalarial drug (SD) used was chloroquine. 
 
 
 
 
 
design, confirm that very likely most of these 
compounds could be used as potential 
antimalarial activity.  
These results prompt several pertinent 
observations: (i) This type of lactams can 
furnish an interesting model for studying the 
interaction of antibiotics with malarial target 
because the possible charge modification of 
substituent of pharmacophore groups; (ii) The 
future flexible pharmacophore site (s) 
geometric conformation enables us to prepare 
molecules for multi-therapeutic materials with 
high selectivity. 
 
Antimalarial screening (in-vitro) 
Nevertheless, moderate to good antimalarial  
activities have been obtained against 
chloroquine resistant Plasmodium falciparum 
K14 strain as outlined in Table 2 with IC50 
varying from 21 to 50 µM. On the other hand, 
no significant antimalarial activity was 
encountered for β-lactam derivatives 1a-1n, all 
of this suggesting a quite strong influence of 
the structure of the considered lactam derivative 
substituted on the anilino group on 
 
 
 
 
 
the mechanism of action involved. 
 
POM analyses  
For the development of bioactive 
compounds, the identification of the active 
structural features is important. Calculations of 
energetics, atomic charges, minimum energy 
structures, geometry, and natural bond orbital 
(NBO) could indicate the electronic density 
distribution of each atom. These systematic 
data, regarding the variation of molecular 
properties, are important for the chemical 
structure and could therefore provide first 
insights into the chemical bonding of b-Lactam 
derivatives (LACD) with various targets.  
The objective of this study is to investigate the 
potential pharmacophore sites of LACD species 
using anti-microbial/ antimalarial screenings 
dependence on pH and comparison with the 
calculated molecular properties. To verify these 
structural features responsible for bioactivity, 
further Petra/Osiris/Molinspiration (POM) 
analyses were carried out for calculation of net 
atomic charges, bond polarity, atomic valence, 
electron delocalization, and lipophicity. 
 
 
 
 
Osiris study  
Structure based design is now fairly routine 
but many potential drugs fail to reach the clinic 
because of ADME-Tox liabilities. One very 
important class of enzymes, responsible for 
many ADMET problems, is the cytochromes 
P450. Inhibition of these or production of 
unwanted metabolites can result in many 
adverse drug reactions. Of the most important 
program, Osiris is already available online. This 
is done by using a combined electronic/ 
structure docking procedure and an example 
will be given here.  
The remarkably well behaved mutagenicity 
of divers synthetic molecules classified in data 
base of CELERON Company of Swiss can be 
used to quantify the role played by various 
organic groups in promoting or interfering with 
the way a drug can be associated with DNA.  
From the data evaluated in Table 2, it 
indicates that 11/28 structures are supposed to 
be non-mutagenic when run through the 
mutagenicity assessment system and as far as 
irritating and reproductive effects are 
concerned, all the 11 compounds are at low risk 
comparable with their analogesd (1k-1n). The 
log P value of a compound, which is the 
logarithm of its partition coefficient between n-
octanol and water, is a well-established measure 
of the compound’s hydrophilicity. Low 
hydrophilicity and therefore high log P values 
may cause poor absorption or permeation. On 
this basis, all the series of compounds 1a–1n 
are having cLogP values under the acceptable 
criteria should be active. The geometrical 
parameter and the aqueous solubility of a 
compound significantly affect its absorption, 
distribution characteristics and bioactivity. 
Typically, a low solubility goes along with a 
bad absorption and therefore the general aim is 
to avoid poorly soluble compounds.  
We have calculated overall drug-score (DS) 
for the compounds 1a–1n as shown in Table  
3. The DS combines drug-likeness, cLogP, 
logS, molecular weight, and toxicity risks in 
one handy value that may be used to judge the 
compound’s overall potential to qualify for a 
drug. The reported compounds 2a–2i showed 
only 5/28 compounds have good DS (DS = 0.5 
or more). That indicates that majority 
 
 
of parameters in drug design have not been 
realized (Table 3). 
 
Molinspiration study  
Modern drug discovery is based in large part 
on high throughput screening of small molecules 
against macromolecular disease targets requiring 
that molecular screening libraries contain drug-
like or lead-like compounds. We have previously 
analyzed known standard references (SR) for 
drug-like and lead-like properties. With this 
information in hand, we have established a 
strategy to design specific drug-like or lead-like 
compounds 1a-1n. Drug likeness is calculated by 
the methodology developed by Molinspiration as 
a virtual screening against various enzymes (Table 
4).  
Themethodisveryrobustandisabletoprocess 
practically all organic and most organometallic 
molecules. Molecular Polar Surface Area TPSA 
is calculated based on the methodology, as a 
sum of fragment contributions. O- and N- 
centered polar fragments are considered (31). 
PSA has been shown to be a very good 
descriptor characterizing drug absorption, 
including intestinal absorption, bioavailability, 
Caco-2 permeability and blood-brain barrier 
penetration. Prediction results of compounds 
1a-1n molecular properties (TPSA, GPCR 
ligand and ICM) are valued (Table 4).  
Oral bioavailability is a desirable property of 
compounds under investigation in the drug 
discovery process. Lipinski’s rule-of-five is a 
simple model to forecast the absorption and 
intestinal permeability of a compound. In the 
rule-of-five model, the compounds are 
considered likely to be well absorbed when they 
possess these attributes-molecular weight < 
500, cLog P < 5, number of H-bond donors < 5, 
number H-bond acceptors < 10, and number of 
rotatable bonds < 10. Lipophilicity (log P value) 
and polar surface area (PSA) values are two 
important properties for the prediction of oral 
bioavailability of drug molecules (32).  
The polar surface area (PSA) is calculated 
from the surface areas that are occupied by 
oxygen and nitrogen atoms and by hydrogen 
atoms attached to them. Thus, the PSA is closely 
related to the hydrogen bonding potential of a 
compound (32). Molecules with PSA values 
  
 
Table 3. Osiris calculations of compounds 1a-1n and 2a-2n.  
 
Entry MW 
 Toxicity Risks[a]   Osiris calculations[b]  
        
MUT TUMO IRRI REP CLP S DL D-S   
          
1a 395     4.34 -4.88 1.82 0.54 
1b 428     4.10 -5.77 3.92 0.14 
1c 394     3.48 -5.03 4.33 0.29 
1d 410     4.05 -5.90 0.89 0.20 
1e 408     3.92 -5.33 4.67 0.35 
1f 442     4.53 -6.07 4.40 0.16 
1g 374     3.31 -4.60 3.01 0.42 
1h 424     4.49 -6.20 1.40 0.20 
1i 408     3.60 -4.51 7.23 0.64 
1j 364     3.59 -5.01 4.40 0.62 
1k 394     3.48 -5.03 2.17 0.17 
1l 4.28     4.10 -5.77 1.74 0.08 
1m 360     2.87 -4.30 0.29 0.16 
1n 410     4.05 -5.90 0.08 0.11 
2a 473     3.13 -4.45 3.81 0.29 
2b 541     4.35 -5.92 5.00 0.11 
2c 507     3.74 -5.18 5.33 0.23 
2d 523     4.31 -6.05 2.22 0.17 
2e 521     4.18 -5.48 5.66 0.27 
1f 555     4.79 -6.45 5.45 0.12 
2g 487     3.56 -4.75 4.27 0.35 
2h 537     4.75 -6.35 2.68 0.16 
2i 521     3.85 -4.66 7.20 0.50 
2j 477     3.85 -5.16 5.61 0.50 
2k 507     3.74 -5.18 4.99 0.23 
2l 541     4.35 -5.92 4.65 0.11 
2m 473     3.13 -4.45 3.44 0.28 
2n 523     4.31 -6.05 1.84 0.17   
 : not toxic;  : highly toxic.  
[a]MUT: mutagenic; TUMO: tumorigenic; IRRI: irritant; REP: reproductive effective.  
[b]CLP: cLogP; S: Solubility; DL: Drug-Likness, DS: Drug-Score. 
 
 
 
 
around of 160 Å or more are expected to exhibit 
poor intestinal absorption (32). Table 4 shows that 
all the compounds are under this limit. It has to be 
kept in mind that log P and PSA 
 
 
 
 
values are only two important, although not 
sufficient criteria for predicting oral absorption 
of a drug (33). To support this contention, note 
that all the compounds have 0-1 violation of the 
 
Table 4. Molinspiration calculations of compounds 1a-1n and 2a-2n.   
Entry 
 Molinspiration calculations    Drug-likeness   
          
TPSA NONI NV VOL GPCRL ICM KI NRL PI EI  
           
1a 65 2 0 327 -0.21 -0.26 -0.31 -0.40 -0.25 -0.26 
1b 65 2 0 354 -0.23 -0.30 -0.28 -0.39 -0.34 -0.30 
1c 65 2 0 340 -0.21 -0.25 -0.32 -0.40 -0.28 -0.28 
1d 65 2 0 371 -0.14 -0.20 -0.21 -0.28 -0.18 -0.18 
1e 65 2 0 358 -0.23 -0.26 -0.35 -0.37 -0.29 -0.30 
1f 65 2 1 371 -0.25 -0.30 -0.32 -0.36 -0.35 -0.32 
1g 65 2 0 344 -0.24 -0.26 -0.35 -0.37 -0.26 -0.28 
1h 65 2 1 388 -0.17 -0.21 -0.25 -0.26 -0.20 -0.21 
1i 65 2 0 358 -0.20 -0.31 -0.26 -0.39 -0.05 -0.27 
1j 56 2 0 315 -0.19 -0.23 -0.32 -0.40 -0.26 -0.27 
1k 65 2 0 340 -0.22 -0.26 -0.31 -0.41 -0.29 -0.29 
1l 65 2 0 354 -0.23 -0.31 -0.28 -0.39 -0.34 -0.32 
1m 65 2 0 327 -0.22 -0.27 -0.31 -0.40 -0.25 -0.27 
1n 65 2 0 371 -0.15 -0.21 -0.21 -0.29 -0.19 -0.20 
2a 77 1 0 429 -0.23 -0.34 -0.34 -0.36 -0.25 -0.31 
2b 80 1 2 453 -0.17 -0.33 -0.18 -0.33 -0.27 -0.29 
2c 80 1 1 439 -0.15 -0.27 -0.20 -0.34 -0.23 -0.27 
2d 80 1 2 469 -0.10 -0.36 -0.16 -0.28 -0.15 -0.23 
2e 80 1 2 456 -0.17 -0.30 -0.23 -0.32 -0.24 -0.28 
1f 80 1 2 469 -0.19 -0.37 -0.22 -0.32 -0.28 -0.31 
2g 80 1 0 442 -0.17 -0.27 -0.23 -0.31 -0.21 -0.27 
2h 80 1 2 486 -0.13 -0.42 -0.22 -0.30 -0.17 -0.28 
2i 80 1 1 456 -0.16 -0.35 -0.17 -0.32 -0.06 -0.26 
2j 71 1 0 413 -0.14 -0.21 -0.20 -0.33 -0.21 -0.26 
2k 80 1 1 439 -0.15 -0.27 -0.20 -0.34 -0.23 -0.27 
2l 80 1 2 453 -0.17 -0.33 -0.18 -0.33 -0.27 -0.29 
2m 80 1 0 425 -0.15 -0.25 -0.19 -0.33 -0.20 -0.25 
2n 80 1 2 469 -0.10 -0.36 -0.16 -0.28 -0.15 -0.23 
 
aTPSA: Total molecular polar surface area; OHN: number of N-H – O interaction; VIOL.: number of violation of fve Lipinsky rules;   
VOL.: volume.  
bGPC: GPCR ligand; ICM: Ion channel modulator; KI: Kinase inhibitor; NRL: Nuclear receptor ligand; PI: Protease inhibitor; EI:  
Enzyme inhibitor. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Molecule in perspectives. 
 
 
 
 
 
Rule-of-five. Two or more violations of the rule 
of five suggest the probability of problems in 
bioavailability (34).  
Drug likeness of compounds 1a-1n is 
tabulated in Table 4. Drug likeness may be 
defined as a complex balance of various 
molecular properties and structure features which 
determine whether particular molecule is similar 
to the known drugs. These properties, mainly 
hydrophobicity, electronic distribution, hydrogen 
bonding characteristics, molecule size and 
flexibility and also presence of various 
pharmacophore features influence the behavior of 
molecule in a living organism, including 
bioavailability, transport properties, affinity to 
proteins, reactivity, toxicity, metabolic stability, 
and many others. Activity of all nine compounds 
and standard drug were rigorously analyzed under 
four criteria of known successful drug activity in 
the areas of GPCR ligand activity, ion channel 
modulation, kinase inhibition activity, and nuclear 
receptor ligand activity. The results are shown for 
all compounds in Table 4 by means of numerical 
assignment. So, likewise 21/21 compounds have 
consistent negative values drug score. Therefore, 
it is readily seen that all the compounds bearing 
no pharmacophore site are expected to have bad 
and near ZERO activity to standard drug used 
based upon these four rigorous criteria (Figure 2). 
 
 
 
 
 
Conclusion 
 
In summary, new β-lactams bearing 
morpholine moieties were synthesized by 
solvent free grinding method in the presence of 
morpholine-4-carbonyl chloride and Et3N. 
Some remarkable benefits of this method is 
avoiding the use of solvent, short reaction time, 
easy purification, moderate to high yield of the 
products, and also presenting moderate to good 
antimalarial activities against a Plasmodium 
falciparum K14 resistant strain. Further works 
are now under current investigation in order to 
improve the structure of potent more active 
compounds and elucidate the mechanism of 
action of these derivatives since the latter 
remains unclear to date.  
The POM analyses of present series 1a-1n 
support the suggested structures of bioactive 
containing pharmacophore sites. It has been 
suggested that some functional groups 
containing non bonded electron pair, constitutes 
an essential dipolar fragment which displayed 
crucial role of biological activity that may be 
responsible for the bio target/drug interaction. It 
was shown that the absence of pharmacophore 
site in the presence of lipophilic groups will not 
enhance activity of the compounds and 
biological absorbance, so as, all candidates of 
the synthesized 1a-1n have modest to poor 
pharmacological properties. 
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